Blair William & Co. IL raised its position in Novanta Inc. (NASDAQ:NOVT – Free Report) by 2.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 448,434 shares of the technology company’s stock after acquiring an additional 10,459 shares during the quarter. Blair William & Co. IL owned approximately 1.25% of Novanta worth $68,507,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in NOVT. Intech Investment Management LLC acquired a new stake in Novanta during the 3rd quarter worth approximately $948,000. Charles Schwab Investment Management Inc. grew its holdings in Novanta by 1.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 439,390 shares of the technology company’s stock worth $78,616,000 after acquiring an additional 4,271 shares in the last quarter. Citigroup Inc. increased its position in shares of Novanta by 179.9% in the 3rd quarter. Citigroup Inc. now owns 34,003 shares of the technology company’s stock valued at $6,084,000 after purchasing an additional 21,854 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Novanta in the 3rd quarter valued at $366,000. Finally, Associated Banc Corp purchased a new stake in shares of Novanta during the 3rd quarter worth $209,000. Institutional investors and hedge funds own 98.35% of the company’s stock.
Novanta Price Performance
Shares of NOVT opened at $135.19 on Thursday. The company has a market capitalization of $4.86 billion, a price-to-earnings ratio of 80.95 and a beta of 1.34. Novanta Inc. has a fifty-two week low of $131.03 and a fifty-two week high of $187.12. The firm has a 50-day simple moving average of $143.63 and a 200-day simple moving average of $159.11. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.81 and a current ratio of 2.79.
Wall Street Analyst Weigh In
Separately, Robert W. Baird cut their price target on Novanta from $169.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd.
View Our Latest Stock Analysis on NOVT
Novanta Profile
Novanta, Inc engages in the provision of core technology solutions to healthcare and advanced industrial original equipment manufacturers. It operates through the following segments: Photonics, Vision, and Precision Motion. The Photonics segment designs, manufactures, and markets photonics-based solutions, including laser scanning and laser beam delivery, CO2 laser, continuous wave and ultrafast laser, and optical light engine products.
Read More
- Five stocks we like better than Novanta
- Why is the Ex-Dividend Date Significant to Investors?
- Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Nike Stock Dips on Earnings: Analysts Weigh in on What’s Next
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Carnival Corporation Will Cruise to Higher Price Points This Year
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.